Innovative, first-of-its-kind technology, Vetscan Imagyst now offers an artificial intelligence (AI) dermatology application and soon will expand equine analysis capabilities in a single platform   

AI dermatology application is now available and AI equine fecal egg count (FEC) analysis will launch in Spring 2023 

Parsippany, N.J. – March 1, 2023 – Zoetis, the world leader in animal health announced the expansion of its multi-purpose, diagnostics platform, Vetscan Imagyst™, to include two new applications, one for AI dermatology, available now; and another for AI equine FEC analysis, which will be available in Spring 2023. These diagnostic additions broaden Vetscan Imagyst testing capabilities beyond existing AI canine and feline fecal analysis, AI blood smear analysis and digital cytology applications to include new in-clinic tests that are fully integrated into the company’s cloud based artificial intelligence capabilities.  With the launch of these applications, Zoetis is continuing to redefine what is possible for in-clinic veterinary diagnosis and animal care across species.    

About Vetscan Imagyst, An All-in-One Technology  

Launched in 2020, Vetscan Imagyst is a first-of-its-kind technology, offering multiple applications in a single diagnostics platform leveraging a combination of image recognition technology, algorithms and cloud-based AI. Using a compact scanner along with AI technology and backed by a global network of expert clinical pathologists, Vetscan Imagyst efficiently delivers a variety of consistent diagnostic tests and results. New applications, like AI dermatology and AI equine FEC analysis, will be easily integrated with existing Vetscan Imagyst testing capabilities, maximizing clinic investment.   

“At Zoetis, we are committed to equipping veterinary healthcare teams with cutting-edge diagnostic tools that provide convenient and efficient solutions to facilitate the best possible care for animals in their practice,” said Lisa Lee, Senior Vice President, Head of Product and Customer Experience, Global Diagnostics at Zoetis. “Adding AI dermatology and AI equine FEC analysis expands the capacity of care that clinicians can provide.”  

Vetscan Imagyst AI Dermatology  

Dermatology visits, specifically for itch, are top reasons for veterinary visits. However, a recent survey of veterinarians indicated that up to 65% of patients do not receive dermatologic diagnostic testing. The introduction of Vetscan Imagyst AI dermatology brings Zoetis one step closer to successfully helping veterinary healthcare teams diagnose and address dermatologic concerns at the time of a pet’s visit. This addition deepens the company’s dermatology portfolio, which has supported veterinarians in the management of nearly 13 million pruritic dogs as a result of control of allergic itch with Apoquel® (oclacitinib tablet) and the treatment of allergic dermatitis in nearly 7 million with Cytopoint®. 

The Vetscan Imagyst AI dermatology application analyzes impression smears and ear and skin swabs to identify yeast, inflammatory cells and bacteria, providing consistent, accurate results within minutes, while freeing up staff.  

Vetscan Imagyst Equine Diagnostics  

Available now, Equine Digital Cytology Image Transfer includes digital review of sample images by board-certified clinical pathologists within the Zoetis network. Cytopathology results are received in less than two hours, 24 hours a day, seven days a week, compared to the traditional 24- to 48-hour wait with off-site lab results, saving veterinary healthcare teams time and shipping expenses. This allows for faster, more informed results to guide treatment decisions. 

“Clinicians know that an accurate diagnosis can make all the difference – ensuring optimal treatment, better outcomes and happier owners and patients – but the reality is that time and capacity in busy clinics get in the way,” said Richard Goldstein, DVM, DACVIM, DECVIM-CA, Vice President, Global Diagnostics Medical Affairs at Zoetis. “Vetscan Imagyst allows veterinary healthcare teams in busy environments to meet the diagnostic and therapeutic needs of their patients quickly and consistently.”  

With the upcoming addition of AI equine FEC analysis this Spring, Vetscan Imagyst will soon deliver fast, reliable and shareable results to equine clinicians within 10 minutes, allowing for rapid detection of Parascaris and strongyles. It is powered by AI, and, in a study, demonstrated up to 99% agreement with board-certified parasitologist results.7 This allows for rapid identification of high shedders versus low shedders to enable strategic targeted deworming protocols to be implemented with our extensive equine parasitology portfolio, consisting of Quest® (moxidectin), Quest Plus® (moxidectin/praziquantel), Anthelcide® EQ Paste (oxibendazole), Strongid®Paste (pyrantel pamoate) and Strongid C 2X® (pyrantel tartrate). 

Visit www.VETSCANIMAGYST.com to learn more about Vetscan Imagyst.